P2.09. Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Jane Sui
Meta Tag
Speaker Jane Sui
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
EGFR-mutant lung cancer
acquired BRAF alterations
clinical characteristics
adenocarcinoma histology
overall survival
treatment discontinuation
combination therapy
treatment-related adverse events
Powered By